Investigation Alert: Long-Term Investors in Gossamer Bio, Inc. (NASDAQ: GOSS) should contact the Shareholders Foundation

An investigation was announced for long-term investors in shares of Gossamer Bio, Inc. (NASDAQ: GOSS) concerning potential breaches of fiduciary duties by certain directors of Gossamer Bio, Inc.

Investors who are current long term investors in Gossamer Bio, Inc. (NASDAQ: GOSS) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: GOSS stocks follows a lawsuit filed against Gossamer Bio, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: GOSS stocks, concerns whether certain Gossamer Bio directors are liable in connection with the allegations made in that lawsuit.

San Diego, CA based Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. Gossamer Bio, Inc. (NASDAQ: GOSS) reported that its annual Total Revenue declined from $114.7 million in 2024 to $48.47 million in 2025, and that its Net Loss increased from $56.52 million in 2024 to $170.37 million in 2025.

On February 23, 2026, Gossamer Bio, Inc. (NASDAQ: GOSS) published a press release and hosted a Special Call announcing topline results for its Phase 3 PROSERA study, which failed to meet the primary endpoint of improved six-minute walk distance (6MWD) at Week 24, with a +13.3 meter placebo-adjusted gain (p-0.0320) failing to meet the required 0.025 alpha threshold. Gossamer attributed this miss to patients at Latin American sites performing particularly well on placebo due to enrollment of a heavily-treated lower-risk population.

Shares of Gossamer Bio, Inc. (NASDAQ: GOSS) declined from $3.87 per share on December 15, 2025, to as low as $0.32 in later March 2026.

According to that complaint filed in the U.S. District Court for the Southern District of California the plaintiff alleges that the defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the study design for the Company's Phase 3 PROSERA study, particularly, controlling for the placebo response at the Latin American testing sites.

Those who purchased shares of Gossamer Bio, Inc. (NASDAQ: GOSS) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.